Euridice Carmona

Montreal, QC, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications

Spotlight on nuclear PD-L1 in ovarian cancer chemoresistance: hidden but mighty.

Spotlight on nuclear PD-L1 in ovarian cancer chemoresistance: hidden but mighty.

Journal: Frontiers in immunology
Published: December 11, 2024

Author Correction: Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence.

Author Correction: Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence.

Journal: Nature communications
Published: May 13, 2024

Author Correction: Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer.

Author Correction: Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer.

Journal: Scientific reports
Published: May 01, 2024

Methylene Blue Metabolic Therapy Restrains In Vivo Ovarian Tumor Growth.

Methylene Blue Metabolic Therapy Restrains In Vivo Ovarian Tumor Growth.

Journal: Cancers
Published: December 17, 2023

GD2 and GD3 gangliosides as diagnostic biomarkers for all stages and subtypes of epithelial ovarian cancer.

GD2 and GD3 gangliosides as diagnostic biomarkers for all stages and subtypes of epithelial ovarian cancer.

Journal: Frontiers in oncology
Published: December 30, 2022

Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer.

Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer.

Journal: Scientific reports
Published: November 28, 2022

Predicting chemoresponsiveness in epithelial ovarian cancer patients using circulating small extracellular vesicle-derived plasma gelsolin.

Predicting chemoresponsiveness in epithelial ovarian cancer patients using circulating small extracellular vesicle-derived plasma gelsolin.

Journal: Journal of ovarian research
Published: October 31, 2022

Prohibitin 1 interacts with p53 in the regulation of mitochondrial dynamics and chemoresistance in gynecologic cancers.

Prohibitin 1 interacts with p53 in the regulation of mitochondrial dynamics and chemoresistance in gynecologic cancers.

Journal: Journal of ovarian research
Published: February 19, 2022

Plasma Gelsolin Confers Chemoresistance in Ovarian Cancer by Resetting the Relative Abundance and Function of Macrophage Subtypes.

Plasma Gelsolin Confers Chemoresistance in Ovarian Cancer by Resetting the Relative Abundance and Function of Macrophage Subtypes.

Journal: Cancers
Published: December 08, 2021

Microdissected Tissue vs Tissue Slices-A Comparative Study of Tumor Explant Models Cultured On-Chip and Off-Chip.

Microdissected Tissue vs Tissue Slices-A Comparative Study of Tumor Explant Models Cultured On-Chip and Off-Chip.

Journal: Cancers
Published: July 05, 2021

Nuclear HKII-P-p53 (Ser15) Interaction is a Prognostic Biomarker for Chemoresponsiveness and Glycolytic Regulation in Epithelial Ovarian Cancer.

Nuclear HKII-P-p53 (Ser15) Interaction is a Prognostic Biomarker for Chemoresponsiveness and Glycolytic Regulation in Epithelial Ovarian Cancer.

Journal: Cancers
Published: June 11, 2021

Carboplatin response in preclinical models for ovarian cancer: comparison of 2D monolayers, spheroids, ex vivo tumors and in vivo models.

Carboplatin response in preclinical models for ovarian cancer: comparison of 2D monolayers, spheroids, ex vivo tumors and in vivo models.

Journal: Scientific reports
Published: May 18, 2021
Showing 1-12 of 37

Last Updated: 09/26/2026